MET and gastric cancer: A phase IB study that evaluated the safety and efficacy of savolitinib in advanced gastric cancer and NSCLC patients with c-MET abnormalities found that the ORR was 9.4 months, disease control rate (DCR) was 39.1% in all patients, and PR was expressed in all gastric cancer patients with MET amplification.[8] Further analysis of the relationship between the curative effect and the copy number of the c-MET gene in gastric cancer showed that all patients with PR had a high MET gene copy number (GCN) expression.